Baxter will acquire Claris Injectables Limited, adding additional generic injectable capabilities to the company’s porfolio.
Baxter International will acquire Claris Injectables Limited for approximately $625 million, the companies said in a Dec. 15, 2016 press announcement. Claris Injectables will add capabilities in production of essential generic injectable medicines, including anesthesia and analgesics, renal, anti-infectives, and critical care in a variety of presentations including bags, vials, and ampoules, to Baxter’s portfolio. The acquisition is expected to close in the second half of 2017.
Claris Injectables, based in Ahmedabad, India, is a global generic injectables pharmaceutical company. The acquisition of Claris Injectables will provide Baxter with a pipeline and marketed portfolio of generic injectables with 11 molecules currently approved in the United States, along with fully integrated research and development expertise and three manufacturing facilities registered with several global regulatory agencies. Through this combination, Baxter anticipates launching seven to nine new products annually during the next several years, increasing to 10–15 anticipated new product launches a year beyond 2019.
“The Claris Injectables acquisition will expand Baxter’s presence in the fast growing, global generic injectable pharmaceuticals space and accelerate our growth trajectory with high-value, essential medicines that will benefit patients worldwide,” said Jose Almeida, chairman and CEO of Baxter in a press announcement. “The capabilities we gain with Claris Injectables will augment and complement our differentiated technologies, expertise, and extensive presence in the hospital channel to create a pathway for Baxter to become a global leader in generic injectables.”
Source: Baxter
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.